SBRT (Stereotactic Body Radiation Therapy) - Stereotactic Body Radiosurgery [PDF]
openaire +1 more source
Predicting prostate cancer recurrence using an atlas‐based tumor control probability model
Abstract Background Recurrence following prostate cancer (PCa) radiation therapy (RT) remains a persistent challenge. Although dose escalation can improve tumor control, it often results in increased toxicity. With an understanding of tumor heterogeneity, identification of radioresistant tumor subvolumes at risk of low tumor control probability (TCP ...
Kazi Ridita Mahtaba +8 more
wiley +1 more source
Dosimetric Challenges of Small Lung Lesions in Low-Density Tissue Treated with Stereotactic Body Radiation Therapy. [PDF]
Das IJ, Ding M, Abazeed ME.
europepmc +1 more source
Stereotactic Body Radiation Therapy to the Prostate With Focal Boost: Analysis of the Primary Endpoint in the DELINEATE Trial Cohort E [PDF]
Julia Murray +9 more
openalex +1 more source
ABSTRACT Background Hilar hepatocellular tumours in dogs pose a significant surgical challenge due to their proximity to major hepatic vessels. Preoperative reduction of tumour volume and vascular involvement may enhance surgical feasibility and improve outcomes.
Hyunglak Son +3 more
wiley +1 more source
Stereotactic body radiation therapy in patients with unresectable hepatocellular carcinoma and portal vein tumor thrombosis. [PDF]
Khosla D +12 more
europepmc +1 more source
Stereotactic MR-guided online adaptive radiation therapy (SMART) for ultracentral thorax malignancies: Results of a phase 1 trial [PDF]
Bradley, Jeffrey D +12 more
core +1 more source
Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents [PDF]
Abraham, Christopher +14 more
core +2 more sources
Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer
Jonathan L. Muldermans +4 more
openalex +1 more source
Treatment‐related changes in the prostate: past, present and future therapies
Radiation therapy alters tumour morphology and immunoprofile in prostate cancer. Residual carcinoma shows distorted glandular architecture on H&E and loss of basal markers with preserved AMACR expression by immunohistochemistry, aiding in the recognition of treatment effect in prostate biopsies.
Katrina Collins, Liang Cheng
wiley +1 more source

